Table 1 Patient characteristics

Age (years)

69 (63–76)

Sex

Male

51 (69%)

Female

23 (31%)

Smoking history

Current or past smoker

66 (89%)

Never smoker

8 (11%)

Brinkman index

840 (500–1105)

LDH (U/L)

207 (177–235)

CRP (mg/dL)

0.35 (0.08–1.43)

HbA1c (%)

5.9 (5.6–6.5)

Glucose (mg/dL)

105 (95–121)

KL-6 (U/mL)

315 (219–586)

Histology

Adenocarcinoma

37 (50%)

Squamous cell carcinoma

26 (35%)

NSCLC, NOS

11 (15%)

Clinical stage

I

2 (3%)

II

5 (7%)

IIIA

22 (30%)

IIIB

25 (34%)

IIIC

13 (18%)

IVA

3 (4%)

Recurrent

4 (5%)

Chemotherapy

Carboplatin/paclitaxel

32 (43%)

Cisplatin/vinorelbine

20 (27%)

Other

4 (5%)

None

18 (24%)

Durvalumab (+)

23 (31%)

RT dose

50 Gy (2.5 Gy/1 fr)

1 (1%)

60 Gy

54 (73%)

66 Gy

19 (26%)

IMRT

3 (4%)

V ₂₀ (%)

22.3 (17.7–30.5)

V ₅ (%)

37.6 (29.0–47.0)

MLD (Gy)

12.6 (10.2–16.4)

Vs5 (cc)

2089 (1476–2626)

Lung volume (cc)

3371 (2927–4247)

ILD onset timing (days)

85 (59–120)